RealVNC mid banner careers
RealVNC mid-banner general
Barr Ellison Solicitors – commercial property
Advertisement: Barclays Eagle Labs
Advertisement: KISS
Advertisement: CPL mid banner
ARM Innovation Hub
Advertisement: Cambridge Network
Advertisement: Mobas mid banner
Advertisement: BKL
Advertisement: Wild Knight Vodka
18 December, 2017 - 17:06 By Tony Quested

Cambridge-US alliance to develop 3D-Printed orphan drugs

Cambridge-based Cycle Pharmaceuticals and Ohio partner Aprecia Pharmaceuticals have joined forces to develop and commercialise orphan drugs using 3D printed technology.

The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilising Aprecia’s proprietary 3DP ZipDose® Technology platform. 
ZipDose® is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food and Drug Administration.

Antonio Benedetti, CEO of Cycle said: “Many rare disease patients do not have a treatment option at all. For those rare diseases where there is an approved pharmaceutical treatment, patients continue to be burdened by sub-optimal drug formulations.
“Aprecia’s ZipDose® 3DP technology can formulate fast-melt pharmaceutical products, incorporating significantly higher amounts of active pharmaceutical ingredient than any other fast-melt technology on the market. As such, this advanced technology can uniquely overcome both pill burden and dysphagia – swallowing difficulties – both of which are life-long, daily issues for so many rare disease patients.”

Don Wetherhold, CEO of Aprecia, added: “We are excited to work with the Cycle team and see important synergies in the companies’ shared mission to address unmet needs in patient care. Cycle specialises in orphan drugs – it has proven that it can deliver quality-of-life improvements to rare disease patients around the world. Aprecia is fully committed to applying its ZipDose® 3DP printing technology to address real-world, daily issues faced by rare disease patients.”

Cycle optimises and increases access to existing pharmaceuticals. Its first orphan drug product, NITYR™ (nitisinone) tablets, is approved in the US and Canada for the treatment of hereditary tyrosinemia type-1. The company’s global headquarters are in Cambridge UK.

• PHOTOGRAPH SHOWS: Antonio Benedetti, Cycle Pharmaceuticals

Advertisement: Barclays Eagle Labs

Newsletter Subscription

Stay informed of the latest news and features